Safety, Tolerability and Pharmacokinetics of a Novel Oral OGA Inhibitor (FNP-223) First-in-Human Phase 1 Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics of FNP-223 (formerly ASN90) in healthy volunteers (HV). Background: Proteinopathies remain largely untreatable and novel therapies are…Temporal disease patterns prior to Progressive Supranuclear Palsy diagnosis
Objective: To identify Progressive Supranuclear Palsy (PSP) disease trajectories, defined as the pattern of diagnoses over time, prior to PSP diagnosis in electronic health records.…Association between Imaging Glymphatic Dysfunction Markers and Clinical Symptoms in Progressive Supranuclear Palsy
Objective: This study aims to explore possible glymphatic dysfunction using diffusion tensor image analysis along the perivascular space (DTI-ALPS) in patients with progressive supranuclear palsy…Brain Target Engagement and Pharmacokinetic-Enzyme Occupancy (PK-EO) Relationship of FNP-223: A Novel Oral OGA Inhibitor for Progressive Supranuclear Palsy – Phase 1 PET Study
Objective: To determine the brain O-GlcNAcase (OGA) occupancy, following a single oral dose of FNP-223 (formerly ASN90) and to determine PK-EO relationship. Background: Preclinical evidence…Clinical subtypes and Radiological patterns in Progressive supranuclear palsy: A Prospective study
Objective: To subclassify Progressive supranuclear palsy (PSP) into cortical and subcortical typesTo identify the clinical and radiological correlation in PSP Background: The 2017 International Parkinson…Connectome of Pathology Stages of Progressive Supranuclear Palsy
Objective: Find the relations between normative FC and seed-to-seed correlations in pathological tau load. Model the FC maps for twelve patients, using post-mortem tau pathology…Enhancing the differential diagnosis of atypical parkinsonian syndromes through a structured clinical acrostic
Objective: To develop a structured clinical acrostic for the differential diagnosis of atypical Parkinsonian syndromes. Background: The diagnosis of atypical parkinsonian syndromes (APS), including dementia…Exploring The Correlation of Neuroimaging, Molecular and Electrophysiological Biomarkers in Patients with Progressive Supranuclear Palsy – Richardson Type
Objective: To correlate blood and electrophysiological biomarkers in Progressive Supranuclear Palsy – Richardson’s type (PSP-RS) patients with brain structural alterations using neuromorphometry. Background: Various biomarkers, including…The Radiographic Overlap Between Normal Pressure Hydrocephalus (NPH) and Progressive Supranuclear Palsy (PSP): When Looks Can Be Deceiving
Objective: To demonstrate the overlap on radiographic metrics between NPH and PSP. Background: The neuroradiological hallmark of NPH is non-obstructive ventriculomegaly (Evans’ index (EI) >0.3).…Retention & Safety in a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo (TOPAZ) in Persons with Neurodegenerative Parkinsonism (NDP)
Objective: To assess retention and safety in the ongoing TOPAZ trial, NCT03924414 Background: People with NDP face a four-fold increased fracture risk, yet preventive treatment…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 42
- Next Page »